Literature DB >> 9042556

The venous thrombotic risk in nonsurgical patients.

J Bouthier1.   

Abstract

The risk of venous thromboembolism is not restricted to surgical situations: previous surgery is encountered in less than one-third of fatal pulmonary embolism cases, and less than 30% of patients hospitalised because of venous thromboembolic events are surgical patients. Some nonsurgical situations, e.g. ischaemic strokes and myocardial infarction (AMI), have been identified as having a risk for thromboembolism. More recently, critically ill patients in intensive care wards have been shown to be exposed to a significant risk of deep venous thrombosis. More often, at-risk situations in nonsurgical patients are less well defined. Clinical trials assessing the efficacy and safety of prophylactic methods in nonsurgical patients are rare, with the exception of those involving stroke and AMI. Several clinical trials have demonstrated that low molecular weight heparins are a suitable alternative to low dose unfractionated heparin in medical patients, offering a decrease in the number of injections and a lower potential for heparin-induced thrombocytopenia. Further research is needed to characterise the extent and duration of the risk of thromboembolism in nonsurgical patients, and the global benefit/risk ratio of various methods of prevention.

Entities:  

Mesh:

Year:  1996        PMID: 9042556     DOI: 10.2165/00003495-199600527-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  40 in total

1.  Accuracy of ultrasound for the diagnosis of deep venous thrombosis in asymptomatic patients after orthopedic surgery. A meta-analysis.

Authors:  P S Wells; A W Lensing; B L Davidson; M H Prins; J Hirsh
Journal:  Ann Intern Med       Date:  1995-01-01       Impact factor: 25.391

2.  Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients.

Authors:  M H Prins; R Gelsema; A K Sing; L R van Heerde; G J den Ottolander
Journal:  Haemostasis       Date:  1989

3.  A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction.

Authors:  C Warlow; G Terry; A C Kenmure; A G Beattie; D Ogston; A S Douglas
Journal:  Lancet       Date:  1973-10-27       Impact factor: 79.321

4.  Identifying patients at risk for thromboembolism. Use of 125I-labeled fibrinogen in patients with acute myocardial infarction.

Authors:  N Cristal; J Stern; M Ronen; C Silverman; W Ho; E Bartov
Journal:  JAMA       Date:  1976-12-13       Impact factor: 56.272

5.  [Prevention of deep venous thrombosis of the leg by a very low molecular weight heparin fraction (CY 222) in patients with hemiplegia following cerebral infarction: a randomized pilot study (30 patients)].

Authors:  A Elias; L Milandre; G Lagrange; M F Aillaud; B Alonzo; F Toulemonde; I Juhan-Vague; R Khalil; B Bayrou; A Serradimigni
Journal:  Rev Med Interne       Date:  1990 Jan-Feb       Impact factor: 0.728

Review 6.  Prevention of venous thromboembolic risk in non-surgical patients.

Authors:  J F Bergmann; D Elkharrat
Journal:  Haemostasis       Date:  1996

7.  Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.

Authors:  T E Warkentin; M N Levine; J Hirsh; P Horsewood; R S Roberts; M Gent; J G Kelton
Journal:  N Engl J Med       Date:  1995-05-18       Impact factor: 91.245

8.  Physician practices in the prevention of venous thromboembolism.

Authors:  F A Anderson; H B Wheeler; R J Goldberg; D W Hosmer; A Forcier; N A Patwardhan
Journal:  Ann Intern Med       Date:  1991-10-15       Impact factor: 25.391

9.  Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction.

Authors:  A G Turpie; J G Robinson; D J Doyle; A S Mulji; G J Mishkel; B J Sealey; J A Cairns; L Skingley; J Hirsh; M Gent
Journal:  N Engl J Med       Date:  1989-02-09       Impact factor: 91.245

10.  Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke.

Authors:  S T McCarthy; J Turner
Journal:  Age Ageing       Date:  1986-03       Impact factor: 10.668

View more
  2 in total

1.  [Profile of patients under treatment with heparin of low molecular weight].

Authors:  M Garrote García; M J Iglesias Piñeiro; A López Gil; R Martín Alvarez
Journal:  Aten Primaria       Date:  2002-09-15       Impact factor: 1.137

2.  The profile and frequency of known risk factors or comorbidities for deep vein thrombosis in an urban district hospital in KwaZulu-Natal.

Authors:  Damilola Awolesi; Mergan Naidoo; Mohammed H Cassimjee
Journal:  South Afr J HIV Med       Date:  2016-05-13       Impact factor: 2.744

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.